ALX Oncology Holdings

Filter

År

Typ

Språk

Rensa

2026-04-17 22:05:00 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

2026-04-13 14:30:00 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

2026-02-27 14:00:00 ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update 2,11 USD | -10,21%

2026-02-19 14:33:00 ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 2,60 USD | +12,07%

2026-02-19 14:30:00 ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 2,60 USD | +12,07%

2026-01-30 14:30:21 ALX Oncology Announces Pricing of Underwritten Offering 1,74 USD | +10,83%

2026-01-30 14:15:00 New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer 1,74 USD | +10,83%

2026-01-08 17:00:00 ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference 1,24 USD | +5,08%

2026-01-08 14:30:00 ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 1,24 USD | +5,08%

2025-12-07 14:00:00 ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

2025-11-18 17:00:00 ALX Oncology to Present at Upcoming Investor Conferences 1,63 USD | +4,49%

2025-11-07 14:15:00 ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update 1,38 USD | +16,95%

2025-10-23 18:30:00 ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference 1,75 USD | +8,70%

2025-10-03 15:05:00 ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting 2,18 USD | +14,14%

2025-09-12 14:30:00 ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer 1,06 USD | -10,17%

2025-08-29 18:00:00 ALX Oncology to Participate in Upcoming Investor Conferences in September 1,17 USD | +2,63%

2025-08-12 22:05:00 ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update 0,62 USD | +0,10%

2025-08-05 14:00:00 ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025 0,66 USD | +12,68%

2025-05-30 14:00:21 ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference 0,49 USD | +3,92%

2025-05-20 14:00:00 ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event 0,43 USD | -1,47%

2025-05-13 14:00:00 ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

2025-05-08 14:30:00 ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update 0,46 USD | -4,94%

2025-05-02 14:00:00 ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 0,53 USD | +3,34%

2025-04-25 19:10:00 ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma 0,54 USD | -9,87%

2025-04-25 15:00:00 ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints 0,54 USD | -9,87%

2025-03-06 22:01:00 ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update 1,31 USD | +25,96%

2025-03-05 14:00:00 ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event 1,04 USD | +4,00%

2025-01-23 14:00:00 ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer 1,63 USD | -9,44%

2025-01-22 22:01:00 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules 1,80 USD | +9,09%

2025-01-22 14:00:00 ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors 1,80 USD | +9,09%

2025-01-21 23:00:00 ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI 1,65 USD | -5,17%

2024-12-18 14:00:00 ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium 1,84 USD | +2,79%

2024-12-12 14:00:00 ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 1,42 USD | -5,96%

2024-12-10 15:00:00 ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer 1,58 USD | -8,14%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

ALX Oncology Holdings

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden